McGlinn Cancer Institute at Reading Hospital — West Reading, Pennsylvania

McGlinn Cancer Institute at Reading Hospital is a clinical research site located in West Reading, Pennsylvania, United States 19611.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

McGlinn Cancer Institute at Reading Hospital has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Non-Hodgkin Lymphoma.

Sponsors: Genentech, Inc..

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for McGlinn Cancer Institute at Reading Hospital?

McGlinn Cancer Institute at Reading Hospital has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has McGlinn Cancer Institute at Reading Hospital conducted?

McGlinn Cancer Institute at Reading Hospital has 2 clinical trials on record, with 2 currently active. Their work covers Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Non-Hodgkin Lymphoma.

Is McGlinn Cancer Institute at Reading Hospital accredited by Crixeo Health?

McGlinn Cancer Institute at Reading Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about McGlinn Cancer Institute at Reading Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.